FDA Investigates Oncogenesis Cases Linked to Novartis Zolgensma

Confirmed cases of product-related insertional oncogenesis have moved Zolgensma's theoretical tumorigenicity warning into active regulatory scrutiny, with the FDA now evaluating whether current prescribing information and long-term follow-up study obligations are adequate to address a documented malignancy signal in AAV gene therapy.

Postmarketing adverse event reports submitted to FDA identify tumors of the central and peripheral nervous systems, spinal and paraspinal regions, and kidney in patients treated with Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy. Three cases involve tumors associated with the GLI1 oncogene; in two of those, molecular analysis confirmed Zolgensma AAV vector DNA integration into the host genome, with the construct's promoter region inserted upstream of or within GLI1. The mechanism driving GLI1 overexpression in the third case remains under investigation.

FDA has extended the neoplasia risk designation to Itvisma, the intrathecally administered formulation approved November 24, 2025, on the basis that both products share the same vector and construct. No cases of neoplasia following Itvisma administration have been reported to date. The agency is also monitoring analogous AAV programs, citing two published integration-driven oncogenesis events: a GLI1 integration in the FBX-101 program (Vo et al., NEJM, October 2026) and a PLAG1 integration in the RGX-111 program (Ahrens-Nicklas et al., NEJM, June 2026).

For QA and regulatory leads managing similar AAV programs, the compliance read is direct: the existing 21 CFR Part 600 postmarketing safety reporting framework and current ICH E2E pharmacovigilance planning assumptions around insertional oncogenesis may require reassessment. FDA's expedited review of Zolgensma's prescribing information signals that labeling updates and strengthened long-term follow-up study protocols are likely near-term regulatory actions, not speculative ones. Sponsor Novartis is already conducting long-term follow-up safety studies; FDA is assessing whether their scope is sufficient given the new mechanistic evidence.

FDA maintains that the overall benefit-risk profile for both Zolgensma and Itvisma remains favorable for their approved indications, and has not withdrawn or suspended either product. Healthcare providers are directed to monitor all treated patients for tumor formation and to report adverse events through Novartis Gene Therapies at 1-833-828-3947 or via MedWatch.

The adequacy of Novartis's long-term follow-up study design, and whether FDA mandates protocol amendments or label revisions, will be the measurable checkpoint that defines the regulatory trajectory for the broader AAV gene therapy sector.

Source: FDA Vaccines, Blood & Biologics Safety Communications via FDA.gov, November 6, 2026.